Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Seite 2
Poster presentations:
- Prevalence of outer retinal tubulation (ORT) and association with geographic atrophy (GA) growth among patients in the OAKS and DERBY trials – Kensington Hatcher,
O.D., FAAO – Monday, May 6 – 3:00‑4:45 PM PDT
- Loss of independence in geographic atrophy (GA) - results from the MOSAIC study among patients and caregivers in Europe – Beverly Lui, PharmD – Thursday, May 9 –
8:00‑9:45 AM PDT
- Deep learning-based segmentation of geographic atrophy in fundus autofluorescence: external validation in imaging acquired in a clinical trial – Souvick
Mukherjee, Ph.D. – Thursday, May 9 – 8:00‑9:45 AM PDT
About SYFOVRE (pegcetacoplan injection)
SYFOVRE (pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement
cascade, part of the body’s immune system. SYFOVRE is approved in the United States for the treatment of GA secondary to age-related macular degeneration.
Lesen Sie auch
About Geographic Atrophy (GA)
Geographic atrophy (GA) is an advanced form of age-related macular degeneration and a leading cause of blindness worldwide, impacting more than one million Americans and five million people
worldwide.1,2 It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision. The vision loss caused by GA
severely impairs independence and quality of life by making it difficult to participate in daily activities. On average, it takes only 2.5 years for GA lesions to start impacting the fovea, which
is responsible for central vision.3